Trials / Completed
CompletedNCT01184456
A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- AIDS Healthcare Foundation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Improvement in the rate of bacterial translocation may lead to a decrease in a chronic inflammatory response thereby decreasing CD4 destruction and HIV proliferation. By the addition of probiotics we hope to show a reduction in LPS leading to a decrease in chronic inflammation and therefore an improvement in immune markers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | GanedenBC30, GBI-30, PTA-6086 | 1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days. |
| DRUG | Placebo | 1 capsule per day for 90 days. |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2010-08-19
- Last updated
- 2021-01-13
- Results posted
- 2019-09-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01184456. Inclusion in this directory is not an endorsement.